Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Synergy Pharmaceuticals Inc (SGYP) Targets Root Cause Of Irritable Bowel Syndrome

Page 1 of 2

Irritable bowel syndrome has no organic cause and treating it usually depends on reducing symptoms of chronic abdominal pain, bloating, and gastric discomfort. While there is no drug to cure the condition yet, Irritable Bowel Syndrome can be managed with a number of drugs available. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) is among one of the few companies that are actively involved in looking for the right treatment for this disorder. In this article, I shall discuss what Irritable Bowel Syndrome is and why Synergy should go ahead with its clinical trials to treat Irritable Bowel Syndrome.

What Is Irritable Bowel Syndrome?

Irritable Bowel Syndrome is a collection of gastrointestinal symptoms that do not have any organic cause. The patients often run through a number of tests for allergies, blood work and other diagnostic procedures without anything that can explain their symptoms. They are often referred to psychologists and are prescribed anti-anxiety drugs in order to reduce psychological distress associated with IBS. It is thought that IBS is a psychosomatic disorder that has its roots in anxiety. However, intensive psychological treatment too does not help IBS sufferers all the time. Those who find that their symptoms are not alleviated by stress reduction techniques, dietary changes and exercise often resort to medications that reduce chronic abdominal pain, constipation, bloating and altered bowel habits.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)Synergy’s New Drug May Treat the Root Cause of GI Symptoms

People diagnosed with IBS are often prescribed laxatives, antispasmodics, tricyclic antidepressants, serotonin agonists and other drugs in order to reduce psychological distress and gastrointestinal difficulties. Synergy announced the commencement of Phase I clinical trial of SP-333, which is a guanylate cyclase C (GC-C) agonist. SP-333 is expected to treat inflammatory bowel disease (IBD) and ulcerative colitis. SP-333 has shown promising results in animal studies and is expected to be the first line choice to treat mild-moderate UC patients. The drug is expected to treat GO inflammatory conditions including IBS. SP-333 is a synthetic analog of uroguanylin. Uroguanylin is produced in the intestinal tract and is a peptide hormone that alleviates gastrointestinal difficulties.

SP-333 Meets Unfulfilled Needs

Synergy will be able to fulfill unmet needs among IBS and IBD sufferers as most treatments that are available right now only target superficially and do not treat the root cause. Synergy’s SP-333 behaves like a natural peptide and is expected to treat IBS, IBD and UC efficiently. An estimated 605 of IBS sufferers also suffer from psychological difficulties such as anxiety and depression but it is possible that these conditions are due to physical symptoms over which the patient has no control whatsoever. When the root cause is treated, a patient will not need to be prescribed psychiatric drugs that have severe side effects.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!